Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6021991 | 0.80 | ITGB3 (0.55) | ALDH1A1ITGB3ITGA2B | |
| SCHEMBL6440314 | 0.80 | ITGB3 (0.55) | ALDH1A1ITGB3ITGA2B | |
| SCHEMBL148347 | 0.78 | ALDH1A1 (0.43) | SLC1A1SLC1A3SLC1A2KMT2AMEN1 | |
| SCHEMBL6443111 | 0.78 | SLC7A5 (0.50) | SLC1A1SLC1A3SLC1A2CYP1A2ITGB3 | |
| SCHEMBL17339044 | 0.77 | KMT2A (0.45) | KMT2A | |
| SCHEMBL415413 | 0.77 | KMT2A (0.45) | KMT2A | |
| SCHEMBL14762052 | 0.77 | ALDH1A1 (0.53) | LMNASMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL17167174 | 0.77 | ALDH1A1 (0.53) | LMNASMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL21814470 | 0.77 | ALDH1A1 (0.53) | LMNASMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL20107370 | 0.77 | ALDH1A1 (0.53) | LMNASMN1; SMN2KMT2AALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060147411-A1 | Novel compounds for the treatment of sickle cell disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2006-07-06 | — | — | US | claimed |
| US-7038078-B2 | Methods of synthesizing and using derivatives of [2-(2-aminoethoxy)ethoxy] acetic acid | UNIVERSITY OF MARLYLAND, BALTIMORE (US) | 2006-05-02 | — | — | US | claimed |
| US-20030134989-A1 | Methods of synthesizing and using derivatives of [2-(2-aminoethoxy)ethoxy] acetic acid | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-07-17 | — | — | US | claimed |
| WO-2002042259-A2 | METHODS OF SYNTHESIZING AND USING DERIVATIVES OF [2-(2-AMINOETHOXY)ETHOXY] ACETIC ACID | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2002-05-30 | — | — | WO | claimed |
| US-20180015170-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC (US) | 2018-01-18 | — | — | US | disclosed |
| US-20160082111-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2016-03-24 | — | — | US | disclosed |
| EP-2812008-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | Cerulean Pharma Inc. (US) | 2014-12-17 | — | — | EP | disclosed |
| CN-104208716-A | Cyclodextrin-based polymers for therapeutic delivery | CERULEAN PHARMA INC | 2014-12-17 | — | — | CN | disclosed |
| US-20140328918-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | CERULEAN PHARMA INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140274947-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20130261173-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2013-10-03 | — | — | US | disclosed |
| WO-2013115966-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2013-08-08 | — | — | WO | disclosed |
| US-20110237540-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2011-09-29 | — | — | US | disclosed |
| WO-2011063421-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| US-20060147411-A1 | Novel compounds for the treatment of sickle cell disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2006-07-06 | — | — | US | disclosed |
| US-7038078-B2 | Methods of synthesizing and using derivatives of [2-(2-aminoethoxy)ethoxy] acetic acid | UNIVERSITY OF MARLYLAND, BALTIMORE (US) | 2006-05-02 | — | — | US | disclosed |
| US-20050187407-A1 | Methods of synthesizing and using derivatives of [2-(2-aminoethoxy)ethoxy] acetic acid | SUNBEAM PRODUCTS, INC. | 2005-08-25 | — | — | US | disclosed |
| WO-2004069171-A2 | NOVEL COMPOUNDS FOR THE TREATMENT OF SICKLE CELL DISEASE | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2004-08-19 | — | — | WO | disclosed |
| US-20030134989-A1 | Methods of synthesizing and using derivatives of [2-(2-aminoethoxy)ethoxy] acetic acid | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-07-17 | — | — | US | disclosed |
| WO-2002042259-A2 | METHODS OF SYNTHESIZING AND USING DERIVATIVES OF [2-(2-AMINOETHOXY)ETHOXY] ACETIC ACID | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134989-A1 | Methods of synthesizing and using derivatives of [2-(2-aminoethoxy)ethoxy] acetic acid | ELL, APEH, HACL2 | LMNA 3102/4885SMN1; SMN2 4409/4885SLC1A1 1019/4885 |
| US-20160082111-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | LMNA 2825/4885SMN1; SMN2 1075/4885SLC1A1 2637/4885 |
| US-20140274947-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | LMNA 2825/4885SMN1; SMN2 1075/4885SLC1A1 2637/4885 |
| US-20110237540-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | LMNA 2825/4885SMN1; SMN2 1075/4885SLC1A1 2637/4885 |
| US-20060147411-A1 | Novel compounds for the treatment of sickle cell disease | HBB, MB, HBG1 | LMNA 3907/4885SMN1; SMN2 397/4885SLC1A1 1375/4885 |
| US-20050187407-A1 | Methods of synthesizing and using derivatives of [2-(2-aminoethoxy)ethoxy] acetic acid | ELL, APEH, HACL2 | LMNA 2949/4885SMN1; SMN2 4393/4885SLC1A1 1134/4885 |
| US-20140328918-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | HLA-DRB1, TSG101, IAPP | LMNA 1261/4885SMN1; SMN2 1613/4885SLC1A1 4608/4885 |
| US-20130261173-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | LMNA 2825/4885SMN1; SMN2 1075/4885SLC1A1 2637/4885 |
| US-20180015170-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | LMNA 2825/4885SMN1; SMN2 1075/4885SLC1A1 2637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.